Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amrubicin vs Topotecan in SCLC
NCT00547651Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2007
- Primary completion
- May 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 17
01
Overview
A Phase 3 trial of amrubicin in small cell lung cancer (SCLC), sponsored by Celgene Corporation. Started Sep 2007; status: completed.
02
Drugs
amrubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00547651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00547651.